The association between adverse events and outcome under checkpoint inhibitors: Where is the deal?

ABSTRACT: Recent reports have put into evidence the possibility of a link between immune-related adverse events (IRAEs) and treatment outcome, patients drawing a benefit from treatment being also exposed to the risk to develop toxicity. A still unanswered question remains the biological origin(s) which can sustain and explain such a relationship. The purpose of this review paper is to lay out different potential contributions which can help to understand the IRAEs-outcome link and to propose clinical perspectives taking advantage of this association. In this respect, pharmacokinetics aspects, immunological and immunogenetics implications have been taken into consideration.

SUBMITTER: Milano G 

PROVIDER: S-EPMC7708939 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature